EU Antimicrobial Resistance Report: What New ECDC Data Means for Patient Safety

The EU antimicrobial resistance situation has worsened since 2019, according to the European Centre for Disease Prevention and Control (ECDC), whose latest EARS-Net surveillance figures show carbapenem-resistant Klebsiella pneumoniae bloodstream infections up 61% across the EU/EEA between 2019 and 2024. The same dataset confirms that antimicrobial resistance (AMR) now causes more than 35,000 deaths a year across EU and EEA countries and costs healthcare systems an estimated €11 billion annually. For patients in Germany, France, Italy, Spain, Poland and every other member state, this data is not an abstract public health statistic. It determines whether a routine hospital stay for a hip replacement, chemotherapy or childbirth carries a real risk of an infection that antibiotics can no longer treat.

What the Latest ECDC AMR Report Found

The ECDC's EARS-Net Annual Epidemiological Report, covering 2024 data collected from all EU/EEA countries and remaining the most current comprehensive dataset available as of August 2026, shows a mixed but largely worrying picture. Resistant bloodstream infections tied to several priority pathogens are climbing, even as the bloc works toward binding 2030 reduction targets.

Under the Council Recommendation adopted on 13 June 2023, EU member states committed to five measurable AMR targets by 2030, using 2019 as the baseline year: a 20% cut in total human antibiotic consumption, at least 65% of that consumption coming from the lower-resistance-risk "Access" antibiotic group, and reductions in bloodstream infections caused by MRSA (15%), third-generation cephalosporin-resistant E. coli (10%) and carbapenem-resistant K. pneumoniae (5%). According to the ECDC's own 2026 assessment, the EU is currently not on track to meet four of these five targets.

There is one genuine bright spot. MRSA bloodstream infections fell by 20.4% compared with 2019 levels, the one indicator moving in the right direction. Everything else in the priority pathogen list is moving the wrong way, which is why the ECDC has repeatedly flagged 2026 as a decisive year for member state action.

Which Infections Are Most Concerning for EU Hospitals

Carbapenem-resistant Enterobacterales, particularly Klebsiella pneumoniae, represent the single most alarming trend in the ECDC's current surveillance data because carbapenems are typically the last broadly effective antibiotic class before treatment options run out.

Carbapenem-resistant Klebsiella pneumoniae: bloodstream infections rose 61% EU/EEA-wide from 2019 to 2024, according to ECDC EARS-Net data, moving the bloc further from its 5% reduction target rather than closer to it.
Third-generation cephalosporin-resistant E. coli: the estimated EU incidence stood at 11.03 cases per 100,000 population in the most recent ECDC dataset, keeping this among the most common resistant bloodstream infections diagnosed in EU hospitals.
Carbapenem-resistant Acinetobacter species: also trending upward, a pathogen the ECDC associates strongly with intensive care units and prolonged hospital stays.
Vancomycin-resistant Enterococcus faecium: among the fastest-rising resistant organisms tracked by EARS-Net, complicating treatment for already vulnerable, often immunocompromised, patients.

The ECDC is also running a third European Survey of carbapenem-resistant Enterobacterales (CRE25), currently collecting 2025 hospital data with expanded whole-genome sequencing capacity, which will sharpen the picture of exactly how these pathogens are spreading between hospitals and across borders when results are published.

Why Resistance Is Rising Across the EU

AMR is rising in the EU because of a combination of an ageing population with more chronic illness, cross-border transmission of resistant bacteria, continued overuse of antibiotics in both humans and agriculture, and persistent gaps in hospital infection prevention and control. The ECDC describes this combination as a compounding, structural problem rather than a single cause that can be fixed in isolation.

Geography matters significantly. ECDC surveillance consistently shows higher resistance rates in southern, central and eastern EU member states compared with northern Europe, a pattern that has persisted across multiple reporting years. Countries with historically higher outpatient antibiotic prescribing, greater cross-border patient movement, and under-resourced infection control teams tend to report the steepest resistance figures, while several northern member states with longer-established stewardship programmes report comparatively lower rates.

Dr Diamantis Plachouras, who leads the ECDC's work on antimicrobial resistance and healthcare-associated infections, has put the stakes plainly: "We must ensure that no one in Europe is left without an effective treatment option." ECDC Director Dr Pamela Rendi-Wagner has similarly stressed that "reaching the EU targets by 2030 requires a united, urgent response across the EU to prevent AMR from undermining healthcare," and that doing so is essential to "protecting patients and sustaining the effectiveness of antibiotics for future generations."

The Social Impact: Who Actually Bears the Cost

AMR does not affect all EU citizens equally. Elderly patients, people undergoing cancer treatment, organ transplant recipients, newborns in intensive care, and anyone requiring major surgery face the highest risk from a resistant infection, because their immune systems have the least capacity to fight an infection if the first-line antibiotic fails. A hip replacement or a caesarean section that should carry a low infection risk becomes materially more dangerous when the local resistant-bacteria rate is high.

Lower-income households and patients in under-resourced regional hospitals are disproportionately exposed. Southern, central and eastern member states with higher documented resistance rates often also have hospitals with tighter staffing and infection-control budgets, meaning the populations already facing the weakest access to specialist care are also the ones facing the highest resistance rates. A resistant infection typically means a longer hospital stay, more expensive second- or third-line antibiotics, and a higher chance of readmission, costs that fall on both public health budgets and, in some member states, directly on patients through co-payments. With the EU-wide annual cost of AMR estimated at €11 billion, every euro spent treating resistant infections is a euro not available for other care, a burden ultimately absorbed by taxpayers and patients across the bloc.

What the EU and Member States Are Doing About It

The European Commission and member states have moved on several fronts in 2026, though the ECDC's own assessment is that the pace still lags the scale of the problem. The second EU Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI 2) launched in 2024, runs through the end of 2027, and is backed by a €50 million European Commission grant involving 128 partner organisations across 30 countries. Its remit covers harmonised surveillance, stronger infection prevention and control, behaviourally tailored antibiotic stewardship programmes, and sustained access to essential antibiotics.

On 7 April 2026, the European Commission announced a further €30 million EU4Health investment specifically to strengthen the global medical countermeasures response to AMR, supporting bodies including the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research & Development Partnership (GARDP), both aimed at accelerating new antibiotic development, an area where the commercial pipeline has stalled for years.

At hospital level, antibiotic stewardship programmes are being rolled out more systematically across member states, with hospital pharmacists increasingly positioned at the centre of multi-professional stewardship teams. The ECDC has been explicit that education campaigns alone have had only marginal effect on prescribing behaviour, which is why the current push emphasises organisational structures, prescribing audits and restricted-access protocols for last-resort antibiotics rather than awareness messaging alone.

This is the wider context behind the ECDC's own framing that 2026 is a decisive year: the surveillance data confirms the direction of travel is wrong on four of five 2030 targets, the funding and joint-action infrastructure to respond is now in place, but the resistant-infection trend lines have not yet turned, which is precisely why hospital-level stewardship enforcement, not just national strategy documents, is now the ECDC's central message to member states.

What EU Patients and Families Can Do Now

Individual action will not close an EU-wide resistance gap on its own, but it materially reduces personal risk and supports the wider stewardship effort described above.

Never request antibiotics for viral infections such as colds, flu or most sore throats; ask your GP or pharmacist directly whether an antibiotic is clinically necessary before accepting a prescription.
Complete every prescribed antibiotic course exactly as directed and never share or reuse leftover antibiotics from a previous illness.
Ask about infection-control protocols before elective hospital procedures, particularly if you are elderly, immunocompromised, or scheduled for surgery in a region with higher reported resistance rates.
Keep vaccinations current, since preventing infections in the first place, including seasonal flu and pneumococcal vaccines for older adults, reduces the need for antibiotics altogether.
Report suspected antibiotic misuse or unusually prolonged hospital-acquired infections to your national health authority, since member state reporting quality feeds directly into the EARS-Net data the ECDC uses to track progress.

Readers can follow ongoing EU policy and public health developments through health articles from Baba International, alongside our broader public health coverage tracking how EU institutions respond to emerging risks.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

What is the ECDC's latest data on antimicrobial resistance in the EU?

The ECDC's EARS-Net Annual Epidemiological Report, based on 2024 data from all EU/EEA countries, shows carbapenem-resistant Klebsiella pneumoniae bloodstream infections up 61% since 2019, alongside more than 35,000 AMR-related deaths a year and roughly €11 billion in annual healthcare costs across the EU/EEA.

Which EU countries have the highest antibiotic resistance rates?

ECDC surveillance consistently finds higher resistance rates in southern, central and eastern EU member states, while several northern member states report comparatively lower rates, a pattern linked to prescribing habits, healthcare resourcing and infection-control capacity.

Is the EU on track to meet its 2030 antimicrobial resistance targets?

No. According to the ECDC's own 2026 assessment, the EU is not on track to meet four of the five targets set out in the Council Recommendation of 13 June 2023, with only the reduction in MRSA bloodstream infections currently moving in the right direction.

What is the EU doing to fight antimicrobial resistance in 2026?

The EU is funding EU-JAMRAI 2, a €50 million joint action running through 2027 across 30 countries, and announced a further €30 million EU4Health investment on 7 April 2026 to support new antibiotic development through CARB-X and GARDP, alongside expanded hospital-level antibiotic stewardship programmes.